中段心房利钠肽前体对肥厚型心肌病预后的预测价值
该前瞻性多中心队列纳入357例肥厚型心肌病患者,基线检测MR-proANP与NT-proBNP。中位随访23个月,32例发生主要终点。MR-proANP与NT-proBNP均与主要终点强相关且ROC曲线下面积无显著差异,但多因素逐步回归中仅MR-proANP、NYHA分级和LVEF进入最佳预测模型。
要点
- MR-proANP与NT-proBNP均与HCM患者主要终点强相关。
- 两者ROC曲线下面积无显著差异。
- 多因素模型中MR-proANP、NYHA分级和LVEF为独立预测因子。
核心结论
- MR-proANP是预测HCM患者死亡和心力衰竭相关事件的有价值生物标志物。
研究设计与样本
- 前瞻性多中心队列研究,纳入357例来自不同欧洲中心的肥厚型心肌病患者,基线进行临床、心电图和超声心动图评估并检测MR-proANP与NT-proBNP。
主要发现
- 中位年龄52岁(IQR:36-65),中位随访23个月,32例发生主要终点(死亡6例、心脏移植8例、左心室辅助装置植入1例、心力衰竭住院17例)。
- NT-proBNP和MR-proANP均与主要终点强相关(p<10-4),两者ROC曲线下面积无显著差异。
- 多因素逐步回归分析中,预测结局的最佳模型包括NYHA 1-2 vs 3-4(HR=0.35,95%CI 0.16-0.77,p<0.01)、LVEF(HR=0.96,95%CI 0.94-0.98,p=0.0005)和MR-proANP(HR=3.77,95%CI 2.01-7.08,p<0.0001)。
临床怎么用
- 在HCM患者风险评估中可检测MR-proANP,结合NYHA分级和LVEF识别高危患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: N-terminal probrain natriuretic peptide (NT-proBNP) predicts mortality and the development of heart failure in hypertrophic cardiomyopathy (HCM). Mid-regional proatrial natriuretic peptide (MR-proANP) is a stable by-product of production of atrial natriuretic peptide. We sought to compare the prognostic value of MR-proANP and NT-proBNP in HCM. METHODS: We prospectively enrolled a cohort of patients with HCM from different European centres and followed them. All patients had clinical, ECG and echocardiographic evaluation and measurement of MR-proANP and NT-proBNP at inclusion. RESULTS: Of 357 patients enrolled, the median age was 52 (IQR: 36-65) years. MR-proANP and NT-proBNP were both independently associated with age, weight, New York Heart Association (NYHA) class, left ventricular ejection fraction (LVEF), wall thickness and left atrial dimension. During a median follow-up of 23 months, 32 patients had a primary end point defined as death (n=6), heart transplantation (n=8), left ventricular assist device implantation (n=1) or heart failure hospitalisation (n=17). Both NT-proBNP and MR-proANP (p<10-4) were strongly associated with the primary endpoint, and the areas under the receiver operating characteristic (ROC) curves for both peptides were not significantly different. However, in a multiple stepwise regression analysis, the best model for predicting outcome was NYHA 1-2 vs 3-4 (HR=0.35, 95% CI 0.16 to 0.77, p<0.01), LVEF (HR=0.96, 95% CI 0.94 to 0.98, p=0.0005) and MR-proANP (HR=3.77, 95% CI 2.01 to 7.08, p<0.0001). CONCLUSIONS: MR-proANP emerges as a valuable biomarker for the prediction of death and heart failure related events in patients with HCM.
引用
- Bégué C, Mörner S, Brito D, et al. Mid-regional proatrial natriuretic peptide for predicting prognosis in hypertrophic cardiomyopathy. Heart. 2019. PMID: 31350276. doi:10.1136/heartjnl-2019-314826
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。